Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 4/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 8/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8908543 | 0.85 | OPRM1 (0.45) | RIPK1OPRM1OPRL1MEN1KMT2A | |
| SCHEMBL8918676 | 0.80 | MEN1 (0.45) | OPRM1OPRL1MEN1KMT2AHDAC4 | |
| SCHEMBL890129 | 0.77 | HDAC4 (0.47) | OPRM1OPRL1MEN1KMT2AHDAC4 | |
| SCHEMBL755740 | 0.77 | MEN1 (0.48) | OPRM1OPRL1MEN1KMT2AHDAC4 | |
| SCHEMBL13747630 | 0.76 | TRPM8 (0.47) | OPRM1OPRL1MEN1KMT2AHDAC4 | |
| Hydrochloric Acid SCHEMBL7486109 | 0.76 | HDAC4 (0.46) | OPRM1OPRL1MEN1KMT2AHDAC4 | |
| SCHEMBL888867 | 0.75 | HDAC4 (0.45) | OPRM1OPRL1MEN1KMT2AHDAC4 | |
| SCHEMBL19578172 | 0.73 | MEN1 (0.40) | OPRM1OPRL1MEN1KMT2AHDAC4 | |
| SCHEMBL12861273 | 0.71 | OPRM1 (0.52) | OPRM1OPRL1MEN1KMT2AHDAC4 | |
| SCHEMBL7259343 | 0.71 | HDAC4 (0.44) | OPRM1OPRL1MEN1KMT2AHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188132-B2 | Linked dibenzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | RIPK1 3538/4885OPRM1 2228/4885OPRL1 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.